consulting with Exxon was unique: Each summer he would stay at Exxon Research and Engineering for one month. At the beginning of the month he was given a loosely defined topic. He then read and mastered an assembly of open-literature and related company reports. By the end of the month he had this material cogently organized and broken into problems to be solved in collaboration with engineers at Exxon. At Ken’s retirement Exxon honored his many consulting contributions with a plaque placed in the lobby of the Research and Engineering Center. He also had conventional consulting contracts with many other firms.
Ken’s research neatly divided into two general areas: pharmacokinetics and reaction engineering. His pharmacokinetics work is exemplified by publications such as “Methotrexate Pharmacokinetics” (Journal of Pharmaceutical Sciences, 60, (1128) 1971), “Species Similarities in Pharmacokinetics” (Federation Proceedings, 39, (54) 1980), “Pharmacokinetics and Cancer Chemotherapy” (Journal of Pharmacokinetics and Biopharmaceutics, 1, (465) 1973), and many other specialized papers. This list of representative titles shows how Ken’s efforts spanned the topic of pharmacokinetics—indeed, founded the topic and defined its scope.
Similarly, his work in reaction engineering was very broad. He began writing the book Chemical Reactor Analysis and Design in 1961; the first edition appeared in 1979 and the second in 1989. Ken’s first publication modeled axial dispersion in reactors, and he continued writing about this topic through much of his career. He was concerned with the difficult topic of parameter identification in reacting systems and later with the implications of lumping the kinetics of systems with a large number of species into more easily understood blocks. He developed a generalized model for estimating the catalyst effectiveness factor in complex systems and on coke formation with catalyst deactivation.